Clinical Research Directory

Inclusion Criteria: * Age ≥18 years, male or female. * High-risk pulmonary nodule/tumor maximum diameter ≤3 cm. * Lesion judged suitable for bronchial navigation-guided diagnosis and treatment. * Ineligible for surgery or refuses surgery/radiotherapy; agrees to primary ablation therapy; provides written informed consent. Exclusion Criteria: * Diffuse bilateral lung lesions unresponsive to ablation. * Contraindication to bronchoscopy or inability to tolerate/cooperate with bronchoscopy. * Severe bleeding tendency or irreversible coagulopathy (PT \>18 s, PTA \<40%).Platelet count \<70×10⁹/L; anticoagulant/antiplatelet therapy discontinued \<1 week before ablation (except prophylactic low-molecular-weight heparin). * Severe pulmonary impairment (maximal voluntary ventilation \<40%). * Other metastatic tumors with widespread metastasis; life expectancy \<3 months. * Poor general condition: widespread metastasis, severe infection, high fever, infectious/radiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic/nutritional disorders. * Eastern Cooperative Oncology Group (ECOG) performance status \>2. * Target lesion received radiotherapy within the past 6 months. * Active hepatitis B, active hepatitis C, known HIV-1/2 antibody positivity, or other active infections judged by the investigator to interfere with treatment. * History of epilepsy, psychosis, or cognitive impairment. * Pregnant/lactating females; males or females planning conception during the trial. * Other conditions deemed inappropriate by the investigator.